Format

Send to

Choose Destination
See comment in PubMed Commons below
Ecancermedicalscience. 2014 Jul 10;8:442. doi: 10.3332/ecancer.2014.442. eCollection 2014.

The Repurposing Drugs in Oncology (ReDO) Project.

Author information

1
Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium ; The George Pantziarka TP53 Trust, London KT1 2JP, UK.
2
Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
3
GlobalCures, Inc, Newton, MA 02459, USA.
4
GlobalCures, Inc, Newton, MA 02459, USA ; Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, MA 02215, USA.

Abstract

The Repurposing Drugs in Oncology (ReDO) Project seeks to repurpose well-known and well-characterised non-cancer drugs for new uses in oncology. The rationale for this project is presented, examining current issues in oncological drug development, challenges for health systems, and existing and future patient needs. In addition to discussing the advantages of repurposing, the paper also outlines some of the characteristics used in the selection of drug candidates by this project. Challenges in moving candidate drugs into clinical trial and subsequent practice are also discussed.

KEYWORDS:

ReDO Project; drug development; drug repurposing; health economics; health policy; metronomics

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center